Aug 5, 2024 1:17 pm EDT bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
Aug 2, 2024 9:25 am EDT bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
Jul 9, 2024 8:00 am EDT bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
Jun 12, 2024 8:00 am EDT bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
May 15, 2024 9:15 am EDT bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
Apr 24, 2024 8:00 am EDT bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
Apr 9, 2024 8:00 am EDT bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
Apr 1, 2024 9:49 am EDT bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 8, 2024 12:45 pm EST bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
